Commentary - Journal of Cellular Immunology (2022) Volume 4, Issue 2
LncZFAS1 Inhibit MPP+-Induced Neuroinflammation Through TXNIP/MIB1 E3 Ubiquitin Ligase/NLRP3 Axis
Peiling Huang MM, Weijun Gong MD*
Department of Neurological Rehabilitation, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China,100144
- *Corresponding Author:
- Weijun Gong
E-mail:gwj197104@ccmu.edu.cn
Received date: January 20, 2022; Accepted date: April 26, 2022
Citation: Huang P, Gong W. LncZFAS1 Inhibit MPP+-Induced Neuroinflammation Through TXNIP/MIB1 E3 Ubiquitin Ligase/
NLRP3 Axis. J Cell Immunol. 2022;4(2):72-78.
Copyright: © 2022 Huang P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Neuroinflammation is associated with the occurrence and progression of Parkinson’s disease (PD). Nucleotide-binding domain-like receptor protein-3 (NLRP3) is closely related to pyroptosis in PD-related cells and animal models, such as microglia and SH-SY5Y cells. The novel lncRNA ZFAS1 (LncZFAS1) regulates a variety of signaling pathways and participates in the inflammatory response in various diseases. However, their role in PD remains unclear. Our research found LncZFAS1 overexpression directly interfered with mir590-3p to inhibit thioredoxin-interacting protein (TXNIP) the Mindbomb 1 (MIB1) E3 ubiquitin ligase/NLRP3 pathway, which might reveal a new research approach to the mechanism of PD.
Keywords
LncZFAS1, Parkinson’s disease, Pyroptosis, MIB1, TXNIP, NLRP3
Abbreviations
PD: Parkinson’s Disease; NLRP3: Nucleotide-binding domain-like Receptor Protein-3; LncZFAS1: Long-noncoding RNA ZFAS1; 6-OHDA: 6-hydroxydopamine; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Ca2+: Calcium ion flux; TXNIP: Thioredoxin- Interacting Protein; TRX: Thioredoxin; ZFAS1: ZNFX1 Antisense RNA 1; ZNFX1: Zinc-finger structure, NFX1; miRNAs: MicroRNAs
Introduction
Recently researchers have focused on the role of neuroinflammation in neurodegenerative diseases such as Alzheimer’s disease [1], atrophic lateral sclerosis [2], Huntington’s disease [3], Multiple sclerosis [4] and Parkinson’s disease (PD) [5]. PD is one of the leading neurodegenerative diseases in developed countries and the complete etiological scenario remains unknown. A-synuclein misfolding and aggregation, mitochondrial dysfunction, dysfunctional protein clearance and ubiquitin/proteasome systems, and neuroinflammation have been associated with PD. Harnessing inflammatory responses through targeted modulation of innate and adaptive immune responses has gained increasing interest in recent years as a potential therapeutic strategy. One of our articles, “A Novel Long-Noncoding RNA LncZFAS1 Prevents MPP+-Induced Neuroinflammation Through MIB1 Activation,” was studied on this topic and published online in Molecular Neurobiology in December, 2021 [6]. We explored
the interaction of the LncZFAS1 and miR590-3p/TXNIP/MIB1
E3 ubiquitin ligase/NLRP3 pathway in the inflammation of PD.
TXNIP ubiquitination via MIB1 E3 ubiquitin ligase regulates
NLRP3 inflammasome activation in SH-SY5Y cells. In contrast,
MPTP activated NLPR3 inflammasome through miR590-3p
upregulation and directly interfered with MIB1-dependent
TXNIP ubiquitination. LncZFAS1 overexpression inhibits this
entire pathway through direct interference with miR590-3p,
suggesting a novel research idea in mechanism of PD [6].
An Appropriate Model for PD Neuroinflammatory Study
An appropriate model is the first and most important step in experimental neuropathological studies of PD. There is a clear criterion for PD model selection, but it needs to be further discussed in a PD non-neuroinflammatory study. The PD model includes toxin-based, gene-based, and synucleinbased models [7-11]. The toxin model imitates dopaminergic
neurodegeneration by injecting neurotoxins, studying
oxidative stress, mitochondrial respiratory defects, and
abnormal protein aggregation among the three potentially
important roles in PD pathogenesis [12,13]. The injected toxins
include 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), paraquat, rotenone, and so
on [14,15]. Rotenone and MPTP show little difference in their
ability to use and inhibit the respiratory chain in animals [16].
However, only MPTP has a clear association with the onset of
human PD; in other words, human exposure to MPTP results
in a syndrome similar to the core neurological symptoms of
PD and relatively selective dopaminergic neurodegeneration
[17]. In addition, animal models based on modification of
the gene or synaptic nuclear protein, including mice, rats,
and fruit flies, cannot obtain stable dopaminergic nerve
cell degeneration (i.e., cell death). Instead, they present a
variety of neuropathological changes, including neuronal
atrophy, malnutrition of neurites, and astrocytic proliferation
with α-synaptic nuclear protein-positive LB-like inclusions
[18]. Nevertheless, dopaminergic cell neurodegeneration
changes are consistent in these models; α-synaptic nuclear
proteins in the neurotoxin model represented by MPTP
demonstrate a higher fitting degree of human PD [19,20].
The misfolding of proteins and dysfunction of the ubiquitinproteasome
pathway, leading to the production of α-synaptic
nuclear proteins, is critical to the pathogenesis of PD [21,22].
Neurotoxin-based models (particularly MPTP models) are
important for elucidating the molecular cascade of cell death
in dopaminergic neurons. Our study explored the TXNIP/MIB1
E3 ubiquitin ligase/NLRP3 pathway as one of the ubiquitinproteasome
pathways; therefore, the adopted SH-SY5Y cell
model (MPTP-induced) is appropriate. Gene expression is
intact in the SH-SY5Y genome of major PD pathways, such
as ROS metabolic columns, ubiquitin-proteasome system,
dopamine metabolism, calcium signaling, mitochondria, and
glycolysis [23]. Retinoic acid is often used to make SH-SY5Y
cells morphologically similar to mature primary neurons
and present a dopaminergic phenotype in PD [24-26].
Furthermore, SH-SY5Y cells have the advantages of highthroughput
screening capacity of high proliferation cell lines,
availability of clonal cells, and avoidance of ethical problems
caused by human primary neural cell culture [27].
The Role of NLRP3 in PD Neuroimmunology
Neuroinflammation-mediated pyroptosis in PD neurological cells has been extensively studied [8,29,30]. Pyroptosis of NLRP3 activation in primary microglial cells is the core of PD progression in an MPTP-induced mouse model [31-35]. NLRP3 is an inflammatory complex mainly present in microglia and contains a caspase activation recruitment domain and caspase-1, which promotes the secretion of IL-1/ IL-18 and induces pyroptosis to destroy microglia to further release IL-1 [36-38]. Our results showed that SH-SY5Y cells
generated and activated NLRP3 to induce cellular pyroptosis
[6], revealing the role of NLRP3 and cells other than microglia
in the neuroinflammatory response in PD. Besides, NLRP3
inflammasome activation may aggravate dopaminergic
neuronal loss in Parkinson’s disease [39]. There is a link between
the aggregation of α-synuclein, increased mitochondrial ROS,
and cathepsin B release with the activation of microglial NLRP3
inflammation-mediated pyroptotic cell death of dopaminergic
neurons in the substantia nigra[40]. Mitochondrial generation
of ROS, mitophagy, loss of function of dopaminergic receptors,
and lncRNA, are frequently connect with microglial NLRP3
inflammasome activation [41]. Activators with different
biological activities and molecular structures can activate
NLRP3, indicating that NLRP3 is activated by common cellular
events rather than by physical interactions [42-46]. Common
activators induce cell stress, and NLRP3 senses these cell
pressures. However, it remains unclear how NLRP3 senses cell
stress and which pathways induce climax in the process of
NLRP3 activation and inflammatory body formation [47,48].
Multiple upstream signals are involved in these processes,
including K+ or Cl- efflux [49], calcium ion flux (Ca2+) [50],
lysosomal destruction [51], mitochondrial dysfunction [52],
metabolic changes [53] and trans-Golgi disassembly [54].
Thioredoxin-interacting protein (TXNIP), an endogenous
inhibitor of the thioredoxin (TRX) system, is associated with
importin-α, Jab1, E3 ubiquitin ligase ITCH, Mybbp1a, and NLRP3
[55]. TXNIP expression was increased and TXNIP knockdown
by siRNA weakened the NLRP3 inflammasome activation
response in αSynagg-stimulated mouse microglial cells,
suggesting that TXNIP plays a nodal role in PD inflammation
[56]. A TXNIP centered inflammasome regulation mechanism
has not yet been reported. In our study, NLPR3 activation, ASC
recruitment, caspase-1 cleavage, and IL-1 release were found
to be dependent on TXNIP/TRX1 interaction. Increased TXNIP
ubiquitination by MIB1 E3 ubiquitin ligase can regulate NLRP3
inflammasome activation in SH-SY5Y cell [6]. In the above
chapter, we mention innate immunity and adaptive immunity.
Microglia, the core of the innate immune network, secrete
both anti- and proinflammatory cytokines and chemokines
together with other factors that regulate not only adaptive
immunity, but also neural function and neural homeostasis
[28]. In PD, a- synuclein is associated with activated
microglia and dopaminergic neuronal death. During disease,
dopaminergic neurons accumulate α-synuclein together with
other misfolded proteins (intracellular Lewy body). On injury
or death, neurons release these proteins to the surrounding
neuroenvironment and the modified proteins find their way
to the peripheral lymphatic system. In our study, SH-SY5Y
cell model (MPTP-induced) was used to simulate the partial
process of dopamine neurons immune injury. Microglia
was not involved in this process, which show certain value
to understand the role of other cells in innate and adaptive
immune responses.

Interaction between lncRNA ZFAS1 and miRNAs in PD Neuroimmunology
ZNFX1 antisense RNA 1 (ZFAS1) is transcribed from the antisense direction of the zinc-finger structure NFX1 (ZNFX1), located on chromosome 20q13 [29]. LncZFAS1 has 14 transcripts created through alternative splicing (http:// asia.ensembl.org/Homo_sapiens/Gene/Summary?g= ENSG00000177410; r = 20:49278178–49299600). NR_003604.3, NR_036658.2, NR_003606.3, NR_003605.2 and NR_036659.2 transcripts are 1008, 946, 860, 689 and 504 nucleotides length, respectively [57]. LncZFAS1 is considered as an oncogene in almost all types of cancers, and therefore it is possible to forecast the clinical outcome of patients with different neoplasms by using expression amounts of ZFAS1 [57]. What’s more, lncZFAS1 is involved in inflammatory response processes in a variety of diseases, such as rheumatoid arthritis [58], acute lung injury [59], sepsis [60] and atherosclerosis [61]. ZFAS1 silencing has decreased proliferation, inflammation, autophagy, and enhanced apoptosis via miR-2682–5p/ ADAMTS9 axis in fibroblast-like synoviocytes of rheumatoid arthritis patients [58]. ZFAS1 up-regulation has increased
inflammatory responses and hindered cholesterol effluence
through sponging miR-654–3p and increasing ADAM10 and
RAB22A expressions in the cell line model of atherosclerosis
[61]. Inhibition of lncRNA ZFAS1 expression promotes the
recovery of neurological function in traumatic brain injury [62].
Silencing of lncRNA ZFAS1, activation of the PI3K/AKT pathway,
and increased expression of miR-421 regulate apoptosis and
autophagy in epilepsy-related hippocampal neurons [63].
High expression of lncRNA ZFAS1 is associated with low
levels of CRP, TNF-α, IL-1, and IL-6 in acute stroke patients [64],
possibly because lncRNA ZFAS1 reduces miR-582 expression
and upregulates nitric oxide synthase 3 expression to reduce
pro-inflammatory cytokine production, thereby reducing
inflammation in patients with acute brain stroke [65]. The
relationship between LncZFAS1 and the NLRP3 inflammasome
requires further investigation. MicroRNAs (miRNAs) target
immune transcripts to fine-tune gene expression and turn on
negative feedback loops, which help limit co-stimulation, set
precise cellular activation thresholds, curtail inflammation,
and control lymphocyte growth [66,67]. In a sepsis model, LncZFAS1 aggravates sepsis-induced progression of cardiac
insufficiency by targeting miR-590-3p/NLRP3-mediated
autophagy and pyroptosis [68]. Thus, we hypothesized that
LncZFAS1 might regulate inflammasome activation and
pyroptosis during Parkinson’s disease. E3 ubiquitin ligases
act as the effectors of ubiquitination, a posttranslational
modification characterized by the attachment of ubiquitin
to a target protein. Modification cause protein rapid
degradation by the proteasome or altering its localization
or binding partners. As a member of the RING family of E3
ligases, MIB1 plays an important role in various biological
processes by mediating the degradation of the different
substrates. At the N terminus of MIB1 are two substratebinding
domains termed MZM (Mib-Herc2/ZZ Zinc Finger/
Mib-Herc2) and REP (consisting of two Mib-repeat domains)
that are cumulatively designated the “MIB” domain and which
serve as the primary determinants of target specificity. These
domains then connect via a series of ankyrin repeats to a C
terminus comprised of three RING finger domains [69]. MIB1
expression was increased in pancreatic carcinoma tissues and
MIB1 overexpression reinforced the proliferative and invasive
capacity through the ubiquitin-proteasome pathway [70]. Seo
et al. [71] found that MIB1 was responsible for the proteasomal
degradation-dependent regulation of α-actinin 3 in skeletal
muscle maintenance. Recently, Qin et al. reported that MIB1
overexpression relieved apoptosis and inflammation of cardiac
microvascular endothelial cells during coronary microvascular
dysfunction by targeting the ASK1/p38 pathway [72]. In
agreement with the hypothesis, lncZFAS1 overexpression
directly interfered with mir590-3p to inhibit TXNIP the MIB1 E3
ubiquitin ligase/NLRP3 pathway [6]. Finally, we consider that
LncZFAS1 can be used as an important regulatory target for
neuroinflammatory pathways in PD.
Conclusion
In conclusion, LncZFAS1 is involved in inflammation and pyroptosis in PD through the TXNIP/MIB1 E3 ubiquitin ligase/ NLRP3 axis. This study revealed the potential beneficial role of lncZFAS1 in the progression of PD, which might serve as a new research approach to explore the pathogenesis of PD.
Funding
This work was supported by the Natural Science Foundation of China (81972148), Beijing Municipal Science and Technology Commission Capital Clinical Feature Applied Research Project (Z181100001718205), National Key Research and Development Program of China (2018YFC0115400), and Beijing Natural Science Foundation of China (7222101).
Consent for Publication
All authors whose names appear on the submission agree
with the version to be published.
Competing Interests
The authors declare no competing interests.
References
- Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease:
current evidence and future directions. Alzheimer’s & Dementia. 2016
Jun 1;12(6):719-32.
- Theoharides TC, Tsilioni I. Amyotrophic lateral sclerosis,
neuroinflammation, and cromolyn. Clinical Therapeutics. 2020 Mar
1;42(3):546-9.
- Saba J, Couselo FL, Bruno J, Carniglia L, Durand D, Lasaga M, et
al. Neuroinflammation in Huntington’s disease: A starring role for
astrocyte and microglia. Current Neuropharmacology. 2021 Nov 30.
- das Neves SP, Sousa JC, Sousa N, Cerqueira JJ, Marques F. Altered
astrocytic function in experimental neuroinflammation and multiple
sclerosis. Glia. 2021 Jun;69(6):1341-68.
- Hirsch EC, Standaert DG. Ten unsolved questions about
neuroinflammation in Parkinson’s disease. Movement Disorders.
2021 Jan;36(1):16-24.
- Zhu Z, Huang P, Sun R, Li X, Li W, Gong W. A novel Long-noncoding
RNA LncZFAS1 prevents MPP+-induced neuroinflammation through
MIB1 activation. Molecular Neurobiology. 2022 Feb;59(2):778-99.
- Patricio F, Juárez-Torres D, Patricio-Martínez A, Mendieta L, Pérez-
Severiano F, Montes S, et al. The C-terminal domain of the heavy chain
of tetanus toxin prevents the oxidative and nitrosative stress induced
by acute toxicity of 1-methyl-4-phenylpyridinium, a rat model of
Parkinson’s disease. Neuroscience Research. 2022 Jan 1;174:36-45.
- Mangano EN, Peters S, Litteljohn D, So R, Bethune C, Bobyn J,
et al. Granulocyte macrophage-colony stimulating factor protects
against substantia nigra dopaminergic cell loss in an environmental
toxin model of Parkinson’s disease. Neurobiology of Disease. 2011 Jul
1;43(1):99-112.
- Han J, Kim SJ, Ryu MJ, Jang Y, Lee MJ, Ju X, et al. Chloramphenicol
Mitigates Oxidative Stress by Inhibiting Translation of Mitochondrial
Complex I in Dopaminergic Neurons of Toxin-Induced Parkinson’s
Disease Model. Oxidative Medicine and Cellular Longevity. 2019 Aug
26;2019.
- Kleinknecht A, Popova B, Lázaro DF, Pinho R, Valerius O, Outeiro
TF, et al. C-terminal tyrosine residue modifications modulate
the protective phosphorylation of serine 129 of α-synuclein in
a yeast model of Parkinson’s disease. PLoS Genetics. 2016 Jun
24;12(6):e1006098.
- Popova B, Kleinknecht A, Arendarski P, Mischke J, Wang D,
Braus GH. Sumoylation protects against β-synuclein toxicity in yeast.
Frontiers in Molecular Neuroscience. 2018 Mar 27;11:94.
- Chia SJ, Tan EK, Chao YX. Historical perspective: Models of
Parkinson’s disease. International Journal of Molecular Sciences. 2020
Jan;21(7):2464.
- Boronat-García A, Guerra-Crespo M, Drucker-Colín R. Historical
perspective of cell transplantation in Parkinson’s disease. World
Journal of Transplantation. 2017 Jun 24;7(3):179.
- Tu L, Wu ZY, Yang XL, Zhang Q, Gu R, Wang Q, et al. Neuroprotective
effect and mechanism of baicalin on Parkinson’s disease model
induced by 6-OHDA. Neuropsychiatric Disease and Treatment.
2019;15:3615.
- Vijayanathan Y, Lim FT, Lim SM, Long CM, Tan MP, Majeed AB,
Ramasamy K. 6-OHDA-lesioned adult zebrafish as a useful Parkinson’s
disease model for dopaminergic neuroregeneration. Neurotoxicity
Research. 2017 Oct;32(3):496-508.
- Maegawa H, Niwa H. Generation of mitochondrial toxin rodent
models of Parkinson’s disease using 6-OHDA, MPTP, and rotenone.
InExperimental Models of Parkinson’s Disease. 2021: 95-110.
- Hamadjida A, Frouni I, Kwan C, Huot P. Classic animal models
of Parkinson’s disease: A historical perspective. Behavioural
Pharmacology. 2019 Jun 1;30(4):291-310.
- Menezes R, Tenreiro S, Macedo D, Santos CN, Outeiro TF. From the
baker to the bedside: yeast models of Parkinson’s disease. Microbial
Cell. 2015 Aug 3;2(8):262.
- Zhang L, Zhang L, Li L, Hölscher C. Semaglutide is neuroprotective
and reduces α-synuclein levels in the chronic MPTP mouse model
of Parkinson’s disease. Journal of Parkinson’s disease. 2019 Jan
1;9(1):157-71.
- Bazzu G, Calia G, Puggioni G, Spissu Y, Rocchitta G, Debetto P, et
al. α-Synuclein-and MPTP-Generated Rodent Models of Parkinson’s
Disease and the Study of Extracellular Striatal Dopamine Dynamics: A
Microdialysis Approach. CNS & Neurological Disorders-Drug Targets
(Formerly Current Drug Targets-CNS & Neurological Disorders). 2010
Aug 1;9(4):482-90.
- Zhu YL, Sun MF, Jia XB, Cheng K, Xu YD, Zhou ZL, et al.
Neuroprotective effects of Astilbin on MPTP-induced Parkinson’s
disease mice: Glial reaction, α-synuclein expression and oxidative
stress. International Immunopharmacology. 2019 Jan 1;66:19-27.
- Liu J, Liu W, Li R, Yang H. Mitophagy in Parkinson’s disease: from
pathogenesis to treatment. Cells. 2019 Jul;8(7):712.
- Kovalevich J, Santerre M, Langford D. Considerations for the Use
of SH-SY5Y Neuroblastoma Cells in Neurobiology. InNeuronal Cell
Culture 2021; 9-23.
- Zhang T, Gygi SP, Paulo JA. Temporal proteomic profiling of SHSY5Y
differentiation with retinoic acid using FAIMS and real-time
searching. Journal of Proteome Research. 2020 Oct 15;20(1):704-14.
- Teppola H, Sarkanen JR, Jalonen TO, Linne ML. Morphological
differentiation towards neuronal phenotype of SH-SY5Y
neuroblastoma cells by estradiol, retinoic acid and cholesterol.
Neurochemical Research. 2016 Apr;41(4):731-47.
- Paik S, Somvanshi RK, Kumar U. Somatostatin-mediated changes
in microtubule-associated proteins and retinoic acid–induced neurite
outgrowth in SH-SY5Y cells. Journal of Molecular Neuroscience. 2019 May;68(1):120-34.
- Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in
Parkinson’s disease research: a systematic review. Molecular
Neurodegeneration. 2017 Dec;12(1):1-1.
- Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE.
Inflammation and adaptive immunity in Parkinson’s disease. Cold
Spring Harbor perspectives in medicine. 2012 Jan 1;2(1):a009381.
- Askarian-Amiri ME, Crawford J, French JD, Smart CE, Smith MA,
Clark MB, et al. SNORD-host RNA Zfas1 is a regulator of mammary
development and a potential marker for breast cancer. RNA. 2011
May 1;17(5):878-91.
- Saijo K, Glass CK. Microglial cell origin and phenotypes in health
and disease. Nature Reviews Immunology. 2011 Nov;11(11):775-87.
- Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, et al. MPTP-driven
NLRP3 inflammasome activation in microglia plays a central role in
dopaminergic neurodegeneration. Cell Death & Differentiation. 2019
Feb;26(2):213-28.
- Qin Y, Qiu J, Wang P, Liu J, Zhao Y, Jiang F, Lou H. Impaired
autophagy in microglia aggravates dopaminergic neurodegeneration
by regulating NLRP3 inflammasome activation in experimental
models of Parkinson’s disease. Brain, behavior, and immunity. 2021
Jan 1;91:324-38.
- Wang K, Lu C, Wang T, Qiao C, Lu L, Wu D, et al. Hyperoside
suppresses NLRP3 inflammasome in Parkinson’s disease via
Pituitary Adenylate Cyclase-Activating Polypeptide. Neurochemistry
International. 2022 Jan 1;152:105254.
- de Araújo FM, Cuenca-Bermejo L, Fernández-Villalba E, Costa SL,
Silva VD, Herrero MT. Role of microgliosis and NLRP3 inflammasome in
Parkinson’s disease pathogenesis and therapy. Cellular and Molecular
Neurobiology. 2021 Jan 2:1-8.
- Yan YQ, Fang Y, Zheng R, Pu JL, Zhang BR. NLRP3 Inflammasomes
in Parkinson’s disease and their Regulation by Parkin. Neuroscience.
2020 Oct 15;446:323-34.
- Wang S, Yuan YH, Chen NH, Wang HB. The mechanisms of NLRP3
inflammasome/pyroptosis activation and their role in Parkinson’s
disease. International Immunopharmacology. 2019 Feb 1;67:458-64.
- Mao Z, Liu C, Ji S, Yang Q, Ye H, Han H, et al. The NLRP3
inflammasome is involved in the pathogenesis of Parkinson’s disease
in rats. Neurochemical Research. 2017 Apr;42(4):1104-15.
- Panicker N, Kanthasamy A, Kanthasamy AG. Fyn amplifies NLRP3
inflammasome signaling in Parkinson’s disease. Aging (Albany NY).
2019 Aug 31;11(16):5871.
- Wang S, Yuan YH, Chen NH, Wang HB. The mechanisms of NLRP3
inflammasome/pyroptosis activation and their role in Parkinson’s
disease. International Immunopharmacology. 2019 Feb 1;67:458-64.
- Sarkar S, Malovic E, Harishchandra DS, Ghaisas S, Panicker N,
Charli A, et al. Mitochondrial impairment in microglia amplifies
NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson’s disease. npj Parkinson’s Disease. 2017
Oct 17;3(1):1-5.
- von Herrmann KM, Salas LA, Martinez EM, Young AL, Howard
JM, Feldman MS, et al. NLRP3 expression in mesencephalic neurons
and characterization of a rare NLRP3 polymorphism associated with
decreased risk of Parkinson’s disease. NPJ Parkinson’s disease. 2018
Aug 15;4(1):1-9.
- Liu Q, Zhang D, Hu D, Zhou X, Zhou Y. The role of mitochondria in
NLRP3 inflammasome activation. Molecular Immunology. 2018 Nov
1;103:115-24.
- He Y, Hara H, Núñez G. Mechanism and regulation of NLRP3
inflammasome activation. Trends in Biochemical Sciences. 2016 Dec
1;41(12):1012-21.
- Li Y, Yang G, Yang X, Wang W, Zhang J, He Y, et al. Nicotinic
acid inhibits NLRP3 inflammasome activation via SIRT1 in vascular
endothelial cells. International Immunopharmacology. 2016 Nov
1;40:211-8.
- Ge C, Cheng Y, Fan Y, He Y. Vincristine attenuates cardiac fibrosis
through the inhibition of NLRP3 inflammasome activation. Clinical
Science. 2021 Jun 11;135(11):1409-26.
- Chen DI, Dixon BJ, Doycheva DM, Li B, Zhang Y, Hu Q, et al.
IRE1α inhibition decreased TXNIP/NLRP3 inflammasome activation
through miR-17-5p after neonatal hypoxic–ischemic brain injury in
rats. Journal of Neuroinflammation. 2018 Dec;15(1):1-8.
- Tang T, Gong T, Jiang W, Zhou R. GPCRs in NLRP3 inflammasome
activation, regulation, and therapeutics. Trends in pharmacological
sciences. 2018 Sep 1;39(9):798-811.
- Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome:
molecular activation and regulation to therapeutics. Nature Reviews
Immunology. 2019 Aug;19(8):477-89.
- Di A, Xiong S, Ye Z, Malireddi RS, Kometani S, Zhong M, et al.
The TWIK2 potassium efflux channel in macrophages mediates
NLRP3 inflammasome-induced inflammation. Immunity. 2018 Jul
17;49(1):56-65.
- Katsnelson MA, Rucker LG, Russo HM, Dubyak GR. K+ efflux
agonists induce NLRP3 inflammasome activation independently of
Ca2+ signaling. The Journal of Immunology. 2015 Apr 15;194(8):3937-
52.
- Katsnelson MA, Lozada-Soto KM, Russo HM, Miller BA, Dubyak
GR. NLRP3 inflammasome signaling is activated by low-level
lysosome disruption but inhibited by extensive lysosome disruption:
roles for K+ efflux and Ca2+ influx. American Journal of Physiology-
Cell Physiology. 2016 Jul 1;311(1):C83-100.
- Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin XJ, et
al. New mitochondrial DNA synthesis enables NLRP3 inflammasome
activation. Nature. 2018 Aug;560(7717):198-203.
- Truax AD, Chen L, Tam JW, Cheng N, Guo H, Koblansky AA, et al.
The inhibitory innate immune sensor NLRP12 maintains a threshold
against obesity by regulating gut microbiota homeostasis. Cell Host & Microbe. 2018 Sep 12;24(3):364-78.
- Chen J, Chen ZJ. PtdIns4P on dispersed trans-Golgi network
mediates NLRP3 inflammasome activation. Nature. 2018
Dec;564(7734):71-6.
- Nasoohi S, Ismael S, Ishrat T. Thioredoxin-interacting protein
(TXNIP) in cerebrovascular and neurodegenerative diseases:
regulation and implication. Molecular Neurobiology. 2018
Oct;55(10):7900-20.
- Samidurai M, Palanisamy BN, Carot AB, Zenitsky G, Jin H,
Anantharam V, et al. PKC delta activation promotes Endoplasmic
Reticulum Stress (ERS) and NLR family pyrin domain-containing 3
(NLRP3) inflammasome activation subsequent to αSynuclein-induced
microglial activation: Involvement of Thioredoxin-interacting protein
(TXNIP)/Thioredoxin (Trx) redoxisome pathway. Frontiers in Aging
Neuroscience. 2021;13:377.
- Ghafouri-Fard S, Kamali MJ, Abak A, Shoorei H, Taheri M. LncRNA
ZFAS1: Role in tumorigenesis and other diseases. Biomedicine &
Pharmacotherapy. 2021 Oct 1;142:111999.
- Ye Y, Gao X, Yang N. LncRNA ZFAS1 promotes cell migration and
invasion of fibroblast-like synoviocytes by suppression of miR-27a in
rheumatoid arthritis. Human Cell. 2018 Jan;31(1):14-21.
- Jiang Y, Zhang W. LncRNA ZFAS1 plays a role in regulating the
inflammatory responses in sepsis-induced acute lung injury via
mediating miR-193a-3p. Infection, Genetics and Evolution. 2021 Aug
1;92:104860.
- An L, Yang T, Zhong Y, Yin Y, Li W, Gao H. Molecular pathways
in sepsis-induced cardiomyocyte pyroptosis: Novel finding on long
non-coding RNA ZFAS1/miR-138–5p/SESN2 axis. Immunology
Letters. 2021 Oct 1;238:47-56.
- Tang X, Yin R, Shi H, Wang X, Shen D, Wang X, et al. LncRNA ZFAS1
confers inflammatory responses and reduces cholesterol efflux in
atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A
axis. International Journal of Cardiology. 2020 Sep 15;315:72-80.
- Feng J, Zhou Z, Feng R, Zeng C, Wei M, Hong T. Silencing long
non-coding RNA zinc finger antisense 1 restricts secondary cerebral
edema and neuron injuries after traumatic brain injury. Neuroscience
Letters. 2021 Jun 21;756:135958.
- Hu F, Shao L, Zhang J, Zhang H, Wen A, Zhang P. Knockdown
of ZFAS1 inhibits hippocampal neurons apoptosis and autophagy
by activating the PI3K/AKT pathway via up-regulating miR-421 in
epilepsy. Neurochemical Research. 2020 Oct;45(10):2433-41.
- Wang G, Zhou Y, Zhong T, Song A, Xue Q. The role of blood
lnc?ZFAS1 in acute ischemic stroke: correlation with neurological
impairment, inflammation, and survival profiles. Journal of clinical
Laboratory Analysis. 2022 Feb;36(2):e24219.
- Zhang Y, Zhang Y. lncRNA ZFAS1 improves neuronal injury and
inhibits inflammation, oxidative stress, and apoptosis by sponging
miR-582 and upregulating NOS3 expression in cerebral ischemia/
reperfusion injury. Inflammation. 2020 Aug;43(4):1337-50.
- Braga L, Ali H, Secco I, Giacca M. Non-coding RNA therapeutics
for cardiac regeneration. Cardiovascular Research. 2021 Mar
1;117(3):674-93.
- Vinuesa CG, Rigby RJ, Yu D. Logic and extent of miRNA-mediated
control of autoimmune gene expression. International Reviews of
Immunology. 2009 Jan 1;28(3-4):112-38.
- Liu JJ, Li Y, Yang MS, Chen R, Cen CQ. SP1-induced ZFAS1
aggravates sepsis-induced cardiac dysfunction via miR-590–3p/
NLRP3-mediated autophagy and pyroptosis. Archives of Biochemistry
and Biophysics. 2020 Nov 30;695:108611.
- Sarbanes SL, Blomen VA, Lam E, Heissel S, Luna JM, Brummelkamp
TR, et al. E3 ubiquitin ligase Mindbomb 1 facilitates nuclear delivery of adenovirus genomes. Proceedings of the National Academy of
Sciences. 2021 Jan 5;118(1).
- Zhang B, Cheng X, Zhan S, Jin X, Liu T. MIB1 upregulates IQGAP1
and promotes pancreatic cancer progression by inducing ST7
degradation. Molecular Oncology. 2021 Nov;15(11):3062-75.
- Seo JY, Kang JS, Kim YL, Jo YW, Kim JH, Hann SH, et al. Maintenance
of type 2 glycolytic myofibers with age by Mib1-Actn3 axis. Nature
Communications. 2021 Feb 26;12(1):1-5.
- Qin XF, Shan YG, Gao JH, Li FX, Guo YX. E3 ubiquitin ligase mind
bomb 1 overexpression reduces apoptosis and inflammation of
cardiac microvascular endothelial cells in coronary microvascular
dysfunction. Cellular Signalling. 2022 Mar 1;91:110223.